These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36261902)

  • 101. A review of JAK and IL-23 inhibitors to treat vitiligo.
    Lee H; Cowan TL; Daniel BS; Murrell DF
    Australas J Dermatol; 2023 May; 64(2):204-212. PubMed ID: 36810815
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus.
    Taher ZA; Lauzon G; Maguiness S; Dytoc MT
    Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
    Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
    Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Original article title: "Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial".
    Yaghoobi R; Omidian M; Bagherani N
    BMC Dermatol; 2011 Mar; 11():7. PubMed ID: 21453467
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Topical epigallocatechin-3-gallate in the treatment of vitiligo.
    Hu W; Zhang L; Lin F; Lei J; Zhou M; Xu A
    Australas J Dermatol; 2021 Aug; 62(3):e404-e407. PubMed ID: 34046892
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.
    Renert-Yuval Y; Ezzedine K; Grimes P; Rosmarin D; Eichenfield LF; Castelo-Soccio L; Huang V; Desai SR; Walsh S; Silverberg JI; Paller AS; Rodrigues M; Weingarten M; Narla S; Gardner J; Siegel M; Ibad S; Silverberg NB
    JAMA Dermatol; 2024 Apr; 160(4):453-461. PubMed ID: 38477910
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Topical ruxolitinib: A new treatment for vitiligo.
    Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
    [TBL] [Abstract][Full Text] [Related]  

  • 108. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
    Grossmann MC; Haidari W; Feldman SR
    J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
    [TBL] [Abstract][Full Text] [Related]  

  • 109. New Indication for Topical Ruxolitnib.
    Aschenbrenner DS
    Am J Nurs; 2022 Nov; 122(11):21. PubMed ID: 36261902
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 111. JAK inhibitors for the treatment of vitiligo.
    Inoue S; Suzuki T; Sano S; Katayama I
    J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
    [TBL] [Abstract][Full Text] [Related]  

  • 112.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 113.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.